Research programme: dopamine D3 receptor antagonists - GlaxoSmithKline
Alternative Names: SB-277011; SB-277011A; SB-414796Latest Information Update: 18 Apr 2011
At a glance
- Originator GlaxoSmithKline
- Class Antipsychotics; Smoking cessation therapies; Tetrahydroisoquinolines
- Mechanism of Action Dopamine D3 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Schizophrenia; Smoking withdrawal; Substance-related disorders
Most Recent Events
- 18 Apr 2011 No development reported - Preclinical for Schizophrenia in United Kingdom (unspecified route)
- 18 Apr 2011 No development reported - Preclinical for Smoking withdrawal in United Kingdom (unspecified route)
- 18 Apr 2011 No development reported - Preclinical for Substance-related disorders in United Kingdom (unspecified route)